PYRIDIUM TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
24-10-2022
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
PHENAZOPYRIDINE HYDROCHLORIDE
Tilgjengelig fra:
SEARCHLIGHT PHARMA INC
ATC-kode:
G04BX06
INN (International Name):
PHENAZOPYRIDINE
Dosering :
200MG
Legemiddelform:
TABLET
Sammensetning:
PHENAZOPYRIDINE HYDROCHLORIDE 200MG
Administreringsrute:
ORAL
Enheter i pakken:
250ML
Resept typen:
Prescription
Terapeutisk område:
ANTIPRURITICS AND LOCAL ANESTHETICS
Produkt oppsummering:
Active ingredient group (AIG) number: 0106949002; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2005-07-08
Preparatomtale
PRESCRIBING INFORMATION
Pr
PYRIDIUM
Phenazopyridine Hydrochloride Tablets USP
100 mg and 200 mg
Urinary Tract Analgesic
Date of Preparation:
OCT 24, 2022
Searchlight Pharma Inc.
1600 Notre-Dame West, Suite 312
Montreal, Quebec
H3J 1M1
Submission Control No.: 267654
PYRIDIUM
®
(Phenazopyridine Hydrochloride) – Prescribing information Page 2 of
16
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................... 3
SUMMARY PRODUCT INFORMATION
.................................................... 3
INDICATIONS AND CLINICAL USE
.......................................................... 3
CONTRAINDICATIONS
...............................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................. 4
ADVERSE REACTIONS
................................................................................
6
DRUG INTERACTIONS
................................................................................
7
DOSAGE AND ADMINISTRATION
............................................................ 7
OVERDOSAGE...............................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
.......................................... 8
STORAGE AND STABILITY
........................................................................
9
DOSAGE FORMS, COMPOSITION AND PACKAGING ........................... 9
PART II: SCIENTIFIC INFORMATION
.......................................................... 10
PHARMACEUTICAL
INFORMATION...................................................... 10
DETAILED PHARMACOLOGY
................................................................. 10
TOXICOLOGY
.............................................................................................
10
REFERENCES...............................................................................................
12
PART III: CONSUMER INFORMATION
......................................................... 13
Les hele dokumentet
